The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
October 25th 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Study Provides More Evidence that Statins Help Slow Liver Fibrosis in Hepatitis C
May 5th 2014Patients in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial who were also treated with statins experienced a significant decrease in time to histological disease progression compared to patients who did not receive statin treatment.
Prophylactic Anticoagulation Preferred Over Mechanical Devices
Prophylactic anticoagulation results in a lower risk of dying among patients in the intensive care unit compared with the use of mechanical devices for protection against venous thromboembolism, according to new research.
Do You Support the New Cholesterol Guidelines and Risk Calculator?
April 17th 2014In this edition of Clinical Forum, we asked Cardiology Review editorial board members and an invited guest to comment on the controversial new cholesterol guidelines and risk calculator issued by the American Heart Association (AHA) and American College of Cardiology (ACC) in November 2013.
Updated Guidance Issued on Valvular Heart Disease
April 16th 2014The updated valvular heart disease guidelines issued by the American Heart Association and American College of Cardiology now incorporate transcatheter aortic valve implantation, which is now recommended for patients who are not candidates for surgery and would be expected to survive longer than 1 year after intervention.